Nepafenac
Antiinflammatory Agents, Non-Steroids
Sold as ILEVRO · NEVANAC
- Drug class
- Antiinflammatory Agents, Non-Steroids
- Availability
- Prescription only
- Routes
- Ophthalmic
- Markets covered
- 4
- Products on record
- 20
- FDA reports (12 mo)
- 49
Overview
Nepafenac is an active pharmaceutical ingredient in the Antiinflammatory Agents, Non-Steroids group (S01BC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 15 | May 22, 2026 |
| US United States | FDA | 2 | April 1, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
| EU European Union | EMA | 1 | January 23, 2026 |
GBUnited Kingdom· MHRA
15 products
Uses
1)
How to take
USUnited States· FDA
2 products
Uses
3% is indicated for the treatment of pain and inflammation associated with cataract surgery. 3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 ).
How to take
CACanada· Health Canada
2 products
Uses
3% benzalkonium chloride as preservative propylene glycol For a complete listing see Dosage Forms, Composition and Packaging section. 3% is indicated for management of pain and inflammation associated with cataract surgery.
Geriatrics (≥ 65 years of age):
No overall differences in safety and effectiveness have been observed between elderly and younger patients.
Pediatrics (< 18 years of age):
The safety and effectiveness of ILEVRO in pediatric patients have not been established. The use of ILEVRO in pediatric patients is not recommended. 3% is contraindicated in: Patients who are hypersensitive to nepafenac, to any ingredient in the formulation or component of the container (for a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph) Patients who are hypersensitive to other nonsteroidal anti-inflammatory drugs (NSAIDs).
EUEuropean Union· EMA
1 product
Uses
1)
How to take
Drug interactions
Known interactions involving Nepafenac. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB001011111 · revised May 22, 2026
- [2]FDA DailyMed · 10f411d3-a81e-07… · revised April 1, 2026 [PDF]
- [3]Health Canada (DPD) · 02411393 · revised March 22, 2025
- [4]European Medicines Agency · EMEA/H/C/000818 · revised January 23, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.